PE-22-28 is a synthetic octapeptide derivative of spadin, acting as a selective TREK-1 potassium channel blocker. Research shows rapid-acting antidepressant-like effects through stimulation of hippocampal neurogenesis.

📊Clinical Studies & Results

PE-22-28 has been investigated in preclinical rodent models of depression.

▪Djillani et al. 2017 demonstrated rapid antidepressant-like effects
▪Hippocampal neurogenesis observed within 4 days
▪TREK-1 channel selectivity confirmed in vitro

PE-22-28 is a promising preclinical research tool for fast-acting antidepressant mechanisms.

🏆Benefits

Rapid-onset antidepressant-like activity
Promotes hippocampal neurogenesis
Selective TREK-1 inhibition
No observed sedative or anxiogenic effects

⚠️Possible Side Effects

▪Limited human safety data
▪Transient injection-site irritation
▪Theoretical cardiac risk at high doses
▪Unknown chronic-use profile

🎯Ideal For

→Depression and mood research
→Neurogenesis studies
→TREK-1 channel pharmacology
→Rapid-acting antidepressant development

LABORATORY REAGENT – FOR RESEARCH PURPOSES ONLY

This product is not a drug or food and should be handled by qualified professionals in laboratory conditions. All product information is provided for educational purposes only.

Description

Information:

The product (substance) isn't a food or diet supplement and is not suitable for human consumption.
Keep out of children's reach
Keep container tightly closed.
Store in a dry, cool and shaded place; protect from moisture.
Store only in the original container.
Avoid contact during pregnancy and breast feeding.
Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.